TY - JOUR
T1 - Prognostic Role and Clinical Significance of Tumor-Infiltrating Lymphocyte (TIL) and Programmed Death Ligand 1 (PD-L1) Expression in Triple-Negative Breast Cancer (TNBC)
T2 - A Systematic Review and Meta-Analysis Study
AU - Lotfinejad, Parisa
AU - Jafarabadi, Mohammad Asghari
AU - Shadbad, Mahdi Abdoli
AU - Kazemi, Tohid
AU - Pashazadeh, Fariba
AU - Shotorbani, Siamak Sandoghchian
AU - Niaragh, Farhad Jadidi
AU - Baghbanzadeh, Amir
AU - Vahed, Nafiseh
AU - Silvestris, Nicola
AU - Baradaran, Behzad
N1 - Funding Information:
We gratefully appreciate the professional researchers of the Immunology Research Center. This study was supported by the Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Funding Information:
Acknowledgments: We gratefully appreciate the professional researchers of the Immunology Research Center. This study was supported by the Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Publisher Copyright:
© 2020 by the authors.
PY - 2020/9
Y1 - 2020/9
N2 - This meta-analysis aimed to evaluate the prognostic value of tumor-infiltrating lymphocytes (TILs) and programmed death-ligand 1 (PD-L1), their associations with the clinicopathological characteristics, and the association between their levels in patients with triple-negative breast cancer (TNBC). PubMed, EMBASE, Scopus, ProQuest, Web of Science, and Cochrane Library databases were searched to obtain the relevant papers. Seven studies with 1152 patients were included in this study. Like the level of TILs, there were no significant associations between PD-L1 expression and tumor size, tumor stage, lymph node metastasis, histological grade, and Ki67 (All p-values ≥ 0.05). Furthermore, there was no significant association between PD-L1 expression with overall survival (OS) and disease-free survival (DFS). In assessment of TILs and survival relationship, the results showed that a high level of TILs was associated with long-term OS (hazard ratios (HR) = 0.48, 95% CI: 0.30 to 0.77, p-value < 0.001) and DFS (HR = 0.53, 95% CI: 0.35 to 0.78, p-value < 0.001). The results displayed that tumoral PD-L1 expression was strongly associated with high levels of TILs in TNBC patients (OR = 8.34, 95% CI: 2.68 to 25.95, p-value < 0.001). In conclusion, the study has shown the prognostic value of TILs and a strong association between tumoral PD-L1 overexpression with TILs in TNBC patients.
AB - This meta-analysis aimed to evaluate the prognostic value of tumor-infiltrating lymphocytes (TILs) and programmed death-ligand 1 (PD-L1), their associations with the clinicopathological characteristics, and the association between their levels in patients with triple-negative breast cancer (TNBC). PubMed, EMBASE, Scopus, ProQuest, Web of Science, and Cochrane Library databases were searched to obtain the relevant papers. Seven studies with 1152 patients were included in this study. Like the level of TILs, there were no significant associations between PD-L1 expression and tumor size, tumor stage, lymph node metastasis, histological grade, and Ki67 (All p-values ≥ 0.05). Furthermore, there was no significant association between PD-L1 expression with overall survival (OS) and disease-free survival (DFS). In assessment of TILs and survival relationship, the results showed that a high level of TILs was associated with long-term OS (hazard ratios (HR) = 0.48, 95% CI: 0.30 to 0.77, p-value < 0.001) and DFS (HR = 0.53, 95% CI: 0.35 to 0.78, p-value < 0.001). The results displayed that tumoral PD-L1 expression was strongly associated with high levels of TILs in TNBC patients (OR = 8.34, 95% CI: 2.68 to 25.95, p-value < 0.001). In conclusion, the study has shown the prognostic value of TILs and a strong association between tumoral PD-L1 overexpression with TILs in TNBC patients.
KW - Meta-analysis
KW - Prognosis
KW - Programmed cell death-ligand 1
KW - Triple-negative breast cancer
KW - Tumor-infiltrating lymphocytes
UR - http://www.scopus.com/inward/record.url?scp=85092413471&partnerID=8YFLogxK
U2 - 10.3390/diagnostics10090704
DO - 10.3390/diagnostics10090704
M3 - Review Article
C2 - 32957579
AN - SCOPUS:85092413471
SN - 2075-4418
VL - 10
JO - Diagnostics
JF - Diagnostics
IS - 9
M1 - 704
ER -
